Bleeding on hormone replacement therapy after menopause should be explained, not normalized away.
The 2026 American College of Obstetricians and Gynecologists update changed the safety posture: for most patients with postmenopausal bleeding, the initial evaluation should include both transvaginal ultrasonography and endometrial tissue sampling. [1] [2] That is a stricter message than the older shorthand many women still hear: "If the lining is thin, you are fine."
Most postmenopausal bleeding is not cancer. A JAMA Internal Medicine systematic review and meta-analysis of 129 studies and 40,790 unique patients found that postmenopausal bleeding occurred in approximately 90% of women with endometrial cancer, while about 9% of women with postmenopausal bleeding were diagnosed with endometrial cancer. [3]
That is the reason for balanced urgency: do not panic, but do not self-adjust hormones and wait indefinitely.
Bottom line
If bleeding happens after menopause while using systemic hormone replacement therapy, the useful question is not "Is this a period?" The useful question is: does this bleeding fit an expected hormone replacement therapy regimen pattern, or does it need endometrial evaluation?
The answer depends on uterus status, hormone replacement therapy type, estrogen dose, progestogen dose and schedule, missed doses, time since starting or changing hormone replacement therapy, whether bleeding is heavy or prolonged, endometrial cancer risk factors, ultrasound quality, biopsy needs, and whether bleeding persists or returns. [1] [5]
An eligibility-aware hormone review is useful because bleeding can come from benign hormone replacement therapy adjustment, vaginal or endometrial atrophy, polyps, fibroids, anticoagulants, missed progestogen, unopposed estrogen, hyperplasia, or cancer. Those possibilities do not use the same next step.
What the American College of Obstetricians and Gynecologists changed in 2026
The American College of Obstetricians and Gynecologists Committee Opinion No. 734 from 2018 said transvaginal ultrasound was usually sufficient for an initial episode of postmenopausal bleeding if the endometrial echo was 4 mm or less, because that cutoff had greater than 99% negative predictive value for endometrial cancer. [4]
The 2026 Clinical Practice Update is a focused update to that content. PubMed summarizes it as revised guidance on using transvaginal ultrasonography to triage patients with postmenopausal bleeding. [1] The American College of Obstetricians and Gynecologists public announcement explains the practical shift: ultrasound plus endometrial tissue sampling is now recommended in the initial evaluation for most patients, and the older ultrasound-without-biopsy pathway for endometrial thickness 4 mm or less was revised. [2]
| Guidance point | Older shorthand | Current safer posture |
|---|---|---|
| Initial postmenopausal bleeding | Thin endometrium at 4 mm or less often reassured after ultrasound. [4] | Most patients should have ultrasound plus endometrial tissue sampling as part of initial evaluation. [1] [2] |
| Why the change matters | A thin lining had high negative predictive value in older guidance. [4] | American College of Obstetricians and Gynecologists says ultrasound alone may miss some cancers on initial presentation. [2] |
| Who may still use ultrasound-only triage | Not every person automatically needs the same sequence. | This is a clinician decision for select low-risk cases with a fully visualized thin endometrium and reliable immediate re-evaluation if bleeding continues or returns. [1] [2] |
| Recurrent bleeding | Thin first ultrasound can be reassuring. | Recurrent or persistent bleeding is new information and needs re-evaluation. [4] [7] |
This is not a reason to overbiopsy everyone without discussion. It is a reason not to let a thin ultrasound become a permanent permission slip when bleeding continues, returns, or happens in a higher-risk context.
Why cancer risk is serious but not the most likely cause
The JAMA Internal Medicine meta-analysis gives the clearest two-sided frame. Postmenopausal bleeding was present in approximately 90% of women with endometrial cancer, which makes it an important warning symptom. But the pooled risk of endometrial cancer among women with postmenopausal bleeding was 9%, with estimates varying by hormone therapy use, geography, and time period. [3]
| Number | What it means | What it does not mean |
|---|---|---|
| About 90% | Most endometrial cancers present with postmenopausal bleeding. [3] | Bleeding confirms cancer. |
| About 9% | Most women with postmenopausal bleeding do not have endometrial cancer. [3] | Bleeding can be ignored. |
| 4 mm or less | Older American College of Obstetricians and Gynecologists guidance said this had greater than 99% negative predictive value in an initial episode. [4] | A thin lining rules out every future or high-risk bleeding episode. |
| 5% to 12% | The American College of Obstetricians and Gynecologists 2026 news release says recent studies suggest this proportion of cancers may not be diagnosed on initial presentation when relying on ultrasound alone. [2] | Everyone has the same risk or same diagnostic sequence. |
The evidence is limited in a practical way: one symptom and one ultrasound measurement cannot handle every risk factor, hormone replacement therapy regimen, access barrier, biopsy result, or recurrent bleeding pattern. That is why the pathway has to stay tied to the person, not just to the thickness number.
HRT changes the history, not the need to report bleeding
Hormone therapy can cause unscheduled bleeding, especially during the first months after starting hormone replacement therapy or after a dose or preparation change. Sequential hormone replacement therapy may create a predictable withdrawal bleed, while continuous combined hormone replacement therapy aims for no bleeding after a settling period.
But systemic estrogen in a person with a uterus creates an endometrial-protection question. Estrogen exposure without adequate progestogen can stimulate the lining. Bleeding can reflect missed progestogen, insufficient progestogen for the estrogen dose, an early adjustment phase, atrophy, polyps, fibroids, anticoagulants, infection, hyperplasia, or malignancy. [5]
The British Menopause Society's 2026 joint guideline, a UK menopause guidance document, is useful because it is specifically about unscheduled bleeding on hormone replacement therapy. It says assessment should start with bleeding pattern, hormone replacement therapy preparation, and cancer risk factors; it also recommends checking abdominal and pelvic exam findings and relevant initial tests such as cervical screening, lower genital tract swabs, and body mass index when appropriate. [5]
For U.S. readers, American College of Obstetricians and Gynecologists guidance should drive the diagnostic pathway. The British guidance still helps explain why the clinician asks detailed questions about timing, regimen, progestogen, risk factors, and bleeding pattern rather than simply telling every woman to stop hormone replacement therapy.
HRT timing: when adjustment may be enough, and when investigation moves up
British Menopause Society guidance separates lower-risk early unscheduled bleeding from later, heavier, persistent, or higher-risk bleeding. In low-risk women without endometrial cancer risk factors, it recommends progestogen or hormone replacement therapy-preparation adjustments for up to 6 months if bleeding occurs within 6 months of starting hormone replacement therapy or persists 3 months after a change in hormone replacement therapy dose or preparation. [5]
It recommends urgent transvaginal ultrasound within 6 weeks when first bleeding occurs more than 6 months after starting hormone replacement therapy or more than 3 months after changing hormone replacement therapy. It also recommends urgent ultrasound regardless of timing if bleeding is prolonged or heavy, or if two minor endometrial cancer risk factors are present. [5]
| Bleeding situation on hormone replacement therapy | Safer decision posture |
|---|---|
| Low-risk, light unscheduled bleeding soon after starting hormone replacement therapy | Regimen and progestogen review may be considered while tracking symptoms, depending on local guidance. [5] |
| Bleeding persists after the early adjustment window | Investigation moves up; do not keep adjusting indefinitely. [5] |
| First bleeding more than 6 months after starting hormone replacement therapy | Urgent transvaginal ultrasound within 6 weeks in British Menopause Society guidance; American College of Obstetricians and Gynecologists 2026 also raises the bar for most postmenopausal-bleeding evaluation. [1] [5] |
| Bleeding more than 3 months after changing hormone replacement therapy | Urgent ultrasound within 6 weeks in British Menopause Society guidance. [5] |
| Heavy or prolonged bleeding | Evaluation should accelerate regardless of timing. [5] |
| Major cancer risk factor or several minor risk factors | Cancer-pathway or specialist evaluation becomes more urgent. [5] |
| Recurrent bleeding after a reassuring first evaluation | Re-evaluation is needed; prior reassurance is not permanent. [7] |
The practical message: a short adjustment window is different from an indefinite watch-and-wait plan.
What ultrasound can and cannot answer
Transvaginal ultrasound can measure endometrial thickness and identify some structural clues such as polyps, fibroids, fluid, or poor visualization. It can also show whether the endometrium is uniform and fully visualized.
But ultrasound is not tissue. The Society of Radiologists in Ultrasound consensus statement described transvaginal ultrasound and endometrial biopsy as first-step options depending on risk, imaging quality, clinical setting, and patient preference. [6] The American College of Obstetricians and Gynecologists 2026 update now moves most patients toward both ultrasound and sampling in the initial evaluation. [1] [2]
The British guidance also uses hormone replacement therapy-regimen-specific ultrasound thresholds. In women with unscheduled bleeding, a fully visualized uniform endometrium measuring 4 mm or less on continuous combined hormone replacement therapy or 7 mm or less on sequential hormone replacement therapy is considered low risk in that guideline, with hormone replacement therapy adjustments and continued follow-up. A thickened endometrium above those thresholds should trigger urgent endometrial assessment. [5]
| Ultrasound result | What it can suggest | What still matters |
|---|---|---|
| Thin, fully visualized endometrium | Lower immediate risk, especially in low-risk bleeding contexts. [4] [5] | Recurrent bleeding, risk factors, poor access to follow-up, and 2026 American College of Obstetricians and Gynecologists guidance. [1] [2] |
| Endometrium not fully visualized | Less reassuring. | Sampling, hysteroscopy, or further imaging may be needed. [5] [6] |
| Thickness above threshold | Higher concern for hyperplasia, polyp, or cancer pathway. [5] | Biopsy or hysteroscopy decisions depend on the whole case. |
| Normal first evaluation but bleeding returns | First result does not close the case. | Recurrent bleeding needs renewed assessment. [7] |
Recurrent bleeding should reopen the decision
One cohort followed women after a first episode of postmenopausal bleeding with endometrial thickness 4 mm or less. During follow-up, 25 of 249 women had recurrent bleeding, or 10%. Two of those recurrent-bleeding cases were endometrial carcinoma. [7]
That does not mean recurrent bleeding usually means cancer. It means recurrence changes the probability and should trigger a new decision, not another round of casual reassurance.
Red flags and urgent patterns
Seek urgent medical help for heavy bleeding, soaking pads, large clots, fainting, dizziness, shortness of breath, chest pain, severe pelvic pain, fever, or signs of significant blood loss.
Prompt gynecology review is also important when bleeding is postmenopausal and unexplained, occurs after sex, persists beyond the expected hormone replacement therapy adjustment window, starts late after hormone replacement therapy has been stable, returns after a reassuring evaluation, or occurs with major risk factors such as very high body mass index, Lynch or Cowden syndrome, or several minor risk factors such as diabetes, polycystic ovary syndrome history, or body mass index 30 to 39. [5]
Do not stop or change systemic hormones on your own if the bleeding is heavy, recurrent, or paired with concerning symptoms. The safer sequence is to report the bleeding, clarify whether the regimen makes any bleeding expected, and complete the recommended evaluation.
What to ask a clinician
- Is this expected bleeding for my hormone replacement therapy regimen, or postmenopausal bleeding that needs diagnostic evaluation?
- Under 2026 American College of Obstetricians and Gynecologists guidance, should my initial evaluation include both transvaginal ultrasound and endometrial tissue sampling?
- If ultrasound is done, is the endometrium fully visualized, uniform, and within the relevant threshold for my hormone replacement therapy type?
- Do I have endometrial cancer risk factors that change the urgency or make ultrasound-only triage inappropriate?
- Is my uterus present, and is my progestogen dose, duration, schedule, and adherence adequate for the estrogen dose and route?
- Could missed doses, recent hormone replacement therapy changes, sequential versus continuous combined hormone replacement therapy, anticoagulants, polyps, fibroids, infection, cervical causes, or vaginal atrophy explain the bleeding?
- If the first evaluation is reassuring, what exact bleeding pattern means I should call again?
Related reading:
- hormone replacement therapy contraindications after menopause.
- Hormone therapy after menopause: benefits, risks, and timing.
- Progesterone vs progestin in hormone replacement therapy.
- hormone replacement therapy after hysterectomy.
- Compounded bioidentical hormones after menopause.
References
[1] Updated Guidance Regarding The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol. 2026;148(1):e87-e91. doi:10.1097/aog.0000000000006275 https://pubmed.ncbi.nlm.nih.gov/41990335/
[2] ACOG publishes updated guidance on evaluation of postmenopausal bleeding. https://www.acog.org/news/news-releases/2026/04/acog-publishes-updated-guidance-evaluation-postmenopausal-bleeding
[3] Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(9):1210-1222. doi:10.1001/jamainternmed.2018.2820 https://pubmed.ncbi.nlm.nih.gov/30083701/
[4] ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018;131(5):e124-e129. doi:10.1097/aog.0000000000002631 https://pubmed.ncbi.nlm.nih.gov/29683909/
[5] British Menopause Society. Management of unscheduled bleeding on hormone replacement therapy. https://thebms.org.uk/publications/bms-guidelines/management-of-unscheduled-bleeding-on-hormone-replacement-therapy-hrt/
[6] Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med. 2001;20(10):1025-36. doi:10.7863/jum.2001.20.10.1025 https://pubmed.ncbi.nlm.nih.gov/11587008/
[7] Van Doorn HC, Timmermans A, Opmeer BC, et al. What is the recurrence rate of postmenopausal bleeding in women who have a thin endometrium during a first episode of postmenopausal bleeding?. Acta Obstet Gynecol Scand. 2008;87(1):89-93. doi:10.1080/00016340701763130 https://pubmed.ncbi.nlm.nih.gov/18158632/